Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: LRCX stock price vs STE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STE's multiple
Needs STE P/E.
Implied fair value · at LRCX's multiple
Needs LRCX P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LRCX FY 2026 (ended Jun 28, 2026) · STE FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 16.49x · EV / EBITDA 43.55x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 92% equity / 8% debt
LRCX carries the larger enterprise value at $383.11B against $23.83B; STE trades on the lower EV / Revenue multiple (4.01x vs 16.49x); STE on the lower EV / EBITDA (15.56x vs 43.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LAM RESEARCH CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
STERIS plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.30x
0.27x
Net debt / EBITDA
Leverage against operating earnings
-0.21x
—
Cash and equivalents
Liquid reserves on the balance sheet
$5.58B
—
Total debt
Interest-bearing obligations outstanding
$3.72B
$1.93B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Applied Materials, Inc.
LRCX vs AMAT
KLA CORP
LRCX vs KLAC
ASML HOLDING NV
LRCX vs ASML
TERADYNE, INC
LRCX vs TER
ENTEGRIS INC
LRCX vs ENTG
Johnson & Johnson
LRCX vs JNJ
BAXTER INTERNATIONAL INC
LRCX vs BAX
BECTON DICKINSON & CO
LRCX vs BDX
ZIMMER BIOMET HOLDINGS, INC.
LRCX vs ZBH
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
